Definition

A fixed dose combination of glecaprevir, an inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease, and pibrentasvir, an inhibitor of the HCV non-structural protein 5A (NS5A), with activity against HCV genotypes 1-6. Upon oral administration of glecaprevir/pibrentasvir, glecaprevir inhibits the HCV NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. Pibrentasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.